Syngene International Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
SYNGENE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.5 pts less than Nifty Smallcap 250 and 1.6 pts less than its Healthcare Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Syngene International reported consolidated revenue from operations of ₹8,745 million in Q1 FY26, up about 10.7% year-on-year from ₹7,897 million in Q1 FY25, though down roughly 14% sequentially from ₹10,180 million in Q4 FY25. Consolidated profit after tax rose to ₹867 million from ₹757 million, a 14.5% YoY increase, while EPS (basic) improved to ₹2.16 from ₹1.89. On a standalone basis, revenue grew 10% to ₹7,993 million, but reported PAT was flat at ₹740 million as the prior-year quarter had a one-time exceptional gain of ₹320 million from a fire-insurance claim. Operating profit before tax and exceptional items jumped about 46% on a consolidated basis, indicating healthy underlying margin expansion. The board also recommended a final dividend of ₹1.25 per share and allotted 402,439 shares to the employee welfare trust.
Underlying business momentum looks solid with double-digit revenue growth and a meaningful jump in core operating profit, which should be viewed positively by shareholders despite the muted headline PAT print caused by the prior-year exceptional item. The recommended dividend adds a modest income cushion, while the auditor's unqualified limited review removes any governance overhang.